title: [Aiming to develop biochemical biomarkers for Parkinson's disease and related disorders].
abstract: In Parkinson's disease (PD), its diagnosis, measurement of progression and response to therapeutic intervention currently rely upon clinical observation. However, there remains a critical need for validated biomarkers for PD. Among proteins in cerebrospinal fluid (CSF) there is ample biochemical, pathological, and genetic evidence that the metabolism of α-synuclein (α-syn) plays a crucial role in the pathogenesis of PD. We first reported that PD patients had significantly lower α-syn levels in their CSF than the control groups. We then investigated the levels of α-syn oligomers in CSF using a specific self-developed ELISA. The levels of α-syn oligomers were significantly higher in the PD compared to the controls, with a sensitivity of 75.0% and a specificity of 87.5% for the diagnosis of PD, demonstrating that CSF α-syn oligomers can be a useful biomarker for diagnosis of PD. We have recently developed a proteomic profiling strategy for PD. CSF proteins were purified with C8 magnetic beads, and mass spectra were obtained by mass spectrometry. By building a Support vector machine classifier, PD and multiple system atrophy (MSA) were classified effectively with good cross-validation accuracy. A proteomic pattern classification method can increase the accuracy of clinical diagnosis of PD and MSA.
authors.affiliation: Department of Molecular Pathobiology of Brain Diseases (Neurology), Kyoto Prefectural University of Medicine.
authors.forename: Takahiko
authors.initials: T
authors.lastname: Tokuda
mesh_terms: D015415:Biomarkers / Q000032:analysis*; D006801:Humans; D010300:Parkinson Disease / Q000175:diagnosis*; D051844:alpha-Synuclein / Q000134:cerebrospinal fluid*
chemical_list: D015415:Biomarkers; D051844:alpha-Synuclein